Kala Pharmaceuticals
OverviewSuggest Edit
Kala Pharmaceuticals, Inc. (Kala) is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Kala’s lead program, a shelf-stable MPP nanosuspension of an ophthalmic corticosteroid, is in clinical trials for the treatment of post-surgical ocular inflammation, dry eye disease, and meibomian gland disease.
Kala is also advancing its novel, small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD). Beyond ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health, respiratory and gastrointestinal diseases, and other indications.
| Type | Public | |
| Founded | 2009 | |
| HQ | Watertown, US | Map |
| Website | kalarx.com |
Key People/Management at Kala Pharmaceuticals
Justin Hanes
Mark Iwicki
Kim Brazzell
Howard B. Rosen
Charlie McDermott
Hongming Chen
Kala Pharmaceuticals Office Locations
Kala Pharmaceuticals Financials and Metrics
Kala Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (FY, 2016) | (33.2m) |
EBIT (FY, 2016) | (32.7m) |
Market capitalization (11-Aug-2020) | 501.2m |
Closing stock price (11-Aug-2020) | 8.9 |
Cash (31-Dec-2016) | 42.5m |
- Source: SEC Filings , SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Revenue | 45.0k | |
General and administrative expense | 4.6m | 7.6m |
R&D expense | 11.4m | 25.0m |
Operating expense total | 16.0m | 32.7m |
- Source: SEC Filings , SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 5.8m | 42.5m |
Current Assets | 7.6m | 45.6m |
PP&E | 738.0k | 594.0k |
Total Assets | 8.4m | 46.3m |
- Source: SEC Filings , SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Net Income | (16.7m) | (33.2m) |
Depreciation and Amortization | 330.0k | 297.0k |
Accounts Payable | 911.0 | (343.0) |
Cash From Operating Activities | (15.1m) | (27.3m) |
- Source: SEC Filings , SEC Filings
Kala Pharmaceuticals Operating Metrics
Show all operating metricsKala Pharmaceuticals Cybersecurity Score
Kala Pharmaceuticals Online and Social Media Presence
Kala Pharmaceuticals's Trends
Kala Pharmaceuticals News and Updates
Kala Pharmaceuticals Blogs
Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease
Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Kala Pharmaceuticals to Present at BofA Securities 2020 Health Care Conference
Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS™ for Dry Eye Disease
Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call
Kala Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares
Kala Pharmaceuticals Frequently Asked Questions
When was Kala Pharmaceuticals founded?
Kala Pharmaceuticals was founded in 2009.
Who are Kala Pharmaceuticals key executives?
Kala Pharmaceuticals's key executives are Justin Hanes, Mark Iwicki and Kim Brazzell.
How many employees does Kala Pharmaceuticals have?
Kala Pharmaceuticals has 37 employees.
Who are Kala Pharmaceuticals competitors?
Competitors of Kala Pharmaceuticals include Biogen, Otonomy and Alimera Sciences.
Where is Kala Pharmaceuticals headquarters?
Kala Pharmaceuticals headquarters is located at 490 Arsenal Way #120Watertown, Watertown.
Where are Kala Pharmaceuticals offices?
Kala Pharmaceuticals has offices in Watertown and Waltham.
How many offices does Kala Pharmaceuticals have?
Kala Pharmaceuticals has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies